Dermatology, MOHS-Micrographic Surgery · Conway, SC
NPI
1639531825
Since 2016
Specialty
Dermatology, MOHS-Micrographic Surgery
Code 207ND0101X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
808 Farrar Dr
Conway, SC, 29526
Phone (843) 234-8700
Groups this clinician bills Medicare through
Medicare paid, 2024
$97K
2,653 services
Medicare patients, 2024
683
Average age 73
Drug cost, 2024
$2.6M
2,345 prescriptions
Company payments, 2025
$484K
From 24 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Fabrizio V Galimberti was code 17003 (destruction skin lesion), 521 times for 133 patients. In total Fabrizio V Galimberti billed 2,653 services in 51 codes, and Medicare paid $97K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-01-02.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 521 | 133 | $1.43 | $747 |
| 11102 Skin Biopsy | Office | 311 | 278 | $19.95 | $6,205 |
| 17000 Destruction Skin Lesion | Office | 255 | 238 | $31.66 | $8,072 |
| 17004 Destruction Skin Lesion | Office | 253 | 219 | $65.05 | $16K |
| 99213 Office E&M - Established | Office | 249 | 223 | $41.99 | $10K |
| 99214 Office E&M - Established | Office | 232 | 190 | $62.42 | $14K |
| 11103 Skin Biopsy | Office | 189 | 121 | $16.17 | $3,056 |
| 99203 Office E&M - New | Office | 174 | 174 | $52.62 | $9,157 |
| 99204 Office E&M - New | Office | 142 | 142 | $80.00 | $11K |
| 17110 Destruction Skin Lesion | Office | 127 | 116 | $44.39 | $5,638 |
| 11900 Skin | Office | 23 | 21 | $13.46 | $310 |
| 96574 Skin | Office | 18 | 16 | $189.32 | $3,408 |
| 11302 Removal or Shaving of Skin Growth | Office | 16 | 15 | $32.99 | $528 |
| 11104 Skin Biopsy | Office | 16 | 16 | $27.98 | $448 |
| 69100 Other Organ Systems | Office | 12 | 12 | $24.03 | $288 |
By year: 2022 $56K for 1,310 services; 2023 $123K for 3,549 services; 2024 $97K for 2,653 services.
Medicare prescription drug claims, 2024
In 2024, the drug Fabrizio V Galimberti prescribed most often to Medicare patients was Ketoconazole, with 446 prescriptions and refills. In total Fabrizio V Galimberti wrote 2,345 Medicare prescriptions that cost $2.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ketoconazole Generic | 446 | 481 | 196 | $7,108 |
| Triamcinolone Acetonide Generic | 322 | 460 | 187 | $4,461 |
| Clobetasol Propionate Generic | 302 | 338 | 152 | $12K |
| Dupixent Pen Dupilumab | 129 | 148 | 22 | $581K |
| Ammonium Lactate Generic | 111 | 136 | 46 | $2,032 |
| Doxycycline Hyclate Generic | 102 | 122 | 66 | $1,990 |
| Tretinoin Generic | 78 | 88 | 34 | $4,430 |
| Clindamycin Phosphate Generic | 76 | 81 | 33 | $2,378 |
| Zoryve Roflumilast | 63 | 127 | 30 | $53K |
| Hydroxyzine Hcl Generic | 60 | 73 | 17 | $449 |
| Prednisone Generic | 57 | 69 | 43 | $150 |
| Metronidazole Generic | 56 | 61 | 30 | $2,494 |
| Opzelura Ruxolitinib Phosphate | 41 | 41 | 18 | $82K |
| Tremfya Guselkumab | 27 | 47 | Under 11 | $373K |
| Otezla Apremilast | 25 | 25 | Under 11 | $123K |
Brand drugs: 512 claims; generic drugs: 1,833 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Fabrizio V Galimberti $484K ($484K in general payments such as food, travel and fees) from 24 companies. The largest payer was UCB, Inc. with $98K.
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. UCB.BR | 121 | $98K |
| Janssen Biotech, Inc. JNJ | 88 | $84K |
| Galderma Laboratories, L.P. GALD.SW | 67 | $76K |
| Abbvie Inc. ABBV | 39 | $44K |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 37 | $42K |
| LEO Pharma Inc. | 61 | $40K |
| Arcutis Biotherapeutics, Inc. ARQT | 32 | $27K |
| E.R. Squibb & Sons, L.L.C. BMY | 24 | $23K |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 15 | $20K |
| Almirall LLC | 15 | $18K |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.